Tribunal remands Transfer Pricing, upholds R&D expense treatment as revenue.

The Tribunal allowed the appeals filed by the assessee for statistical purposes, remanding the matter to the Transfer Pricing Officer for fresh examination of Arm's Length Price using the Transactional Net Margin Method. The appeals filed by the Assessing Officer regarding the treatment of Research and Development expenses were dismissed, upholding the Commissioner of Income Tax (Appeals)'s decision to treat them as revenue expenses.

---

---

Issues Involved:
1. Arm's Length Price (ALP) adjustment for contract manufacturing transactions with Associated Enterprises (AEs).
2. Treatment of research and development expenses as capital or revenue in nature.

Issue-wise Detailed Analysis:

1. Arm's Length Price (ALP) Adjustment for Contract Manufacturing Transactions with AEs:

The primary issue in these appeals pertains to the correctness of the ALP adjustment made to the billing for contract manufacturing by the assessee to its AEs based abroad. The core question is whether the Cost Plus Method (CPM) or the Transactional Net Margin Method (TNMM) is the most appropriate method for determining the ALP of contract manufacturing transactions.

The assessee, a subsidiary of a global confectionery company, manufactures and sells products both domestically and to its AEs. The Transfer Pricing Officer (TPO) rejected the TNMM adopted by the assessee, which compared the net margin realized by the assessee with that of comparable companies. Instead, the TPO applied the CPM, using the gross mark-up on costs for domestic sales as the benchmark for exports to AEs, leading to significant ALP adjustments.

The Tribunal noted that the essential input for applying CPM is finding a "comparable uncontrolled transaction." The domestic sales, which involve substantial marketing and sales promotion efforts by the assessee, were not comparable to the export transactions where such efforts were undertaken by the AEs. The Tribunal emphasized that the two situations-domestic sales with full marketing responsibilities and export sales without such responsibilities-are not comparable due to different Functional, Asset, and Risk (FAR) profiles.

The Tribunal concluded that the authorities below were not justified in applying CPM as the most appropriate method due to the lack of comparable uncontrolled transactions. The TNMM, as adopted by the assessee, was deemed appropriate. However, the Tribunal also criticized the quality of the transfer pricing reports and certifications, leading to the remittance of the matter to the TPO for fresh determination of ALP using TNMM.

2. Treatment of Research and Development Expenses as Capital or Revenue in Nature:

The second issue concerns the disallowance of expenses incurred by the assessee on research and development (R&D) by treating them as capital in nature. The Assessing Officer (AO) had disallowed these expenses, arguing that they resulted in enduring benefits and pertained to the development of new products.

The CIT(A) deleted the disallowance, stating that the expenses were incurred on "laboratory testing of the products" and were routine revenue expenses. The CIT(A) also noted that these expenses did not result in the creation of any intangible capital asset.

The Tribunal upheld the CIT(A)'s decision, agreeing that the expenses were routine and did not create any intangible asset or substantial enduring advantage. The Tribunal found no material to dislodge the CIT(A)'s findings and thus declined to interfere with the deletion of the disallowance.

Conclusion:

The Tribunal allowed the appeals filed by the assessee for statistical purposes, remanding the matter to the TPO for fresh examination of ALP using TNMM. The appeals filed by the Assessing Officer regarding the treatment of R&D expenses were dismissed, upholding the CIT(A)'s decision to treat them as revenue expenses.

---